The Liver Meeting 2022-Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

Video Transcription

Video Summary

Dr. Jack Uetrecht is a leading scientist in the field of idiosyncratic drug-induced liver injury. He has a background in pharmacy, medicine, and pharmacology, and has conducted extensive research on the metabolism of drugs, identification of reactive metabolites, and the immune responses that occur in drug-induced liver injury. <br /><br />In his lecture, Dr. Uetrecht discussed the different types of idiosyncratic drug-induced liver injury, including immune idiosyncrasy and metabolic idiosyncrasy. He presented evidence that immune-mediated responses, involving the activation of specific T cells and the presence of antibodies, are responsible for liver injury in many cases. He also discussed the role of immune tolerance in preventing more severe forms of liver injury. <br /><br />Dr. Uetrecht highlighted the importance of studying the early steps of the immune response to drugs, as this can provide valuable insights into the development of idiosyncratic drug-induced liver injury. He also discussed potential risk factors and interventions that may help reduce the occurrence of idiosyncratic drug-induced liver injury, such as slow dose titration and the release of damage-associated molecular patterns (DAMPs) that can activate inflammasomes. <br /><br />Overall, Dr. Uetrecht emphasized the need for further research to better understand the mechanisms underlying idiosyncratic drug-induced liver injury and to develop strategies for prevention and treatment.

Asset Caption

Presented by Dr. Jack Uetrecht, Pharmacy and Medicine, University of Toronto

The goal of the session is to critically review mechanistic hypotheses of idiosyncratic drug-induced liver injury (iDILI). A better mechanistic understanding of iDILI can be used to improve drug safety as indicated in the Objectives below.

Keywords

idiosyncratic drug-induced liver injury

immune responses

immune idiosyncrasy

metabolic idiosyncrasy

immune tolerance

risk factors

inflammasomes